Orlando, FL -- (SBWIRE) -- 10/09/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Magnum Hunter Resources Corp (NYSE:MHR), Novavax, Inc. (NASDAQ:NVAX).
Magnum Hunter Resources Corp (NYSE:MHR) shares decreased 3.18% to $6.69. The company will host a conference call on Friday, November 8, 2013, at 9:00 a.m. CST to discuss its third quarter 2013 financial and operating results. The Company will issue a Press Release announcing these financial and operating results before the U.S. financial markets open on the morning of the conference call.
Additionally, the company on Oct. 7 announced the election of Mr. Rocky Duckworth to the Company's Board of Directors, effective October 7, 2013. Mr. Duckworth will serve as an independent director of the Company. With the election of Mr. Duckworth, Magnum Hunter's Board of Directors increases to seven members, all of which are non-employee, independent directors, except for Mr. Gary C. Evans, the Company's Chairman of the Board and Chief Executive Officer.
Are investors worried about the recent updates with MHR? Find out with a free trend analysis HERE
Novavax, Inc. (NASDAQ:NVAX) shares declined 6.71% to $3.06. The company on Oct. 7 announced that enrollment has begun in a Phase 2 dose-confirmatory clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age.
This randomized, blinded, placebo-controlled Phase 2 study will evaluate the immunogenicity and safety of multiple formulations of Novavax' RSV-F protein nanoparticle vaccine candidate with aluminum phosphate as an adjuvant. The study is scheduled to enroll 720 women of childbearing age who will receive either one or two intramuscular injections at each dose level of vaccine or placebo at days 0 and 28.
Additionally, the company on Sept. 24 announced that it has priced an underwritten public offering of 27,693,000 shares of common stock at a price of $3.14 per share, the closing price of the stock on the previous day, for gross proceeds of approximately $87.0 million. Novavax expects to receive net proceeds, after deducting the underwriting discount, of approximately $82.6 million from the offering.
Is NVAX going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)